RadNet

RadNet, Inc. provides freestanding, fixed-site outpatient diagnostic imaging services in the United States. Its centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders and reduce unnecessary invasive procedures. The firm offers magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures. RadNet was founded by Howard G. Berger in 1980 and is headquartered in Los Angeles, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

RadNet reports strong Q4 earnings, targets AI growth in 2023

RadNet's Q4 2022 performance demonstrated strong revenue and EBITDA growth, fueled by procedural demand and strategic investments in AI and expansion initiatives.
Despite challenges like labor market disruptions and a net loss, the company's focus on innovation, market positioning, and financial discipline bodes well for future profitability and growth.
Opportunities lie in AI revenue growth, de novo center profitability, and market expansion, positioning RadNet as a key player in the radiology industry with a clear path to sustained success.
With a commitment to quality services, shareholder value, and operational excellence, RadNet's strategic vision aligns with industry trends and growth opportunities, setting the stage for continued success and market leadership.

RadNet reports record Q1 revenue and EBITDA growth, eyes AI expansion

RadNet's Q1 2023 showcased strong financial performance and operational improvements. Despite challenges like net loss and labor inflation, the company is strategically positioned for growth through expansion and AI initiatives. Opportunities in advanced imaging services and cancer detection technologies present avenues for future success.

RadNet reports record Q2 earnings, eyes growth amid challenges

RadNet's Q2 2023 performance reflects strong revenue and EBITDA growth, driven by core Imaging Center segment.
While facing challenges like potential Medicare cuts and AI segment delays, the company is optimistic about growth opportunities.
Strategic initiatives in preventative medicine, AI, and outpatient services position RadNet for future success.
With a focus on innovation and financial strength, RadNet aims to capitalize on market shifts and technological advancements.

RadNet reports robust Q3 earnings, eyes growth through AI and partnerships

RadNet's Q3 performance reflects strong revenue growth and financial management, supported by AI division success and strategic initiatives for 2024.
Despite challenges such as staffing shortages and pricing discussions, the company's strengths in liquidity, debt management, and operational focus position it well for future growth.
Opportunities in acquisitions, AI investments, and partnerships offer avenues for expansion and innovation, driving RadNet's market leadership and service excellence.
Overall, RadNet's focus on growth, efficiency, and strategic partnerships underscores its commitment to sustainable success and market resilience in the healthcare industry.

RadNet reports record Q4 earnings, eyes AI growth opportunities

RadNet's Q4 2023 performance was strong, with record revenue and adjusted EBITDA driven by Imaging Center segment growth.
The company's focus on AI, acquisitions, and joint ventures presents growth opportunities but also challenges in reaching expansion targets.
Management's commitment to market leadership and financial strength positions RadNet well for future success and innovation.
RadNet's strategic investments and balance sheet strength support its growth initiatives and potential breakthroughs in AI solutions.

RadNet achieves record Q3 results, eyes AI growth opportunities

RadNet's Q3 2024 performance showcased exceptional financial results, underpinned by revenue growth, operational efficiency, and strategic guidance revisions for the full year.
The company's strengths lie in expansion initiatives, innovative collaborations, and a forward-looking approach towards technology commercialization and digital health advancement.
While facing challenges in regional adoption rates and program implementations, RadNet is well-positioned to capitalize on opportunities through strategic partnerships, AI profitability, and market expansion efforts.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

RadNet, Inc. (NASDAQ:RDNT ) Q1 2023 Earnings Conference Call May 9, 2023 10:30 AM ET Company Participants Howard Berger - Chairman, President & CEO Mark Stolper - Executive VP & CFO Conference Call Participants Brian Tanquilut - Jefferies LLC John Ransom - Raymond James Lawrence Solow - CJS Securities Operator Good morning, and welcome to the RadNet, Inc. First Quarter 2023 Financial Results Call. All participants will be in a listen-only mode.

RadNet, Inc. (RDNT) Q1 2023 Earnings Call Transcript

RadNet (RDNT) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.15 per share a year ago.

RadNet (RDNT) Reports Q1 Loss, Tops Revenue Estimates

LOS ANGELES, May 09, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 363 owned and operated outpatient imaging centers, today reported financial results for its first quarter of 2023.

RadNet Reports First Quarter Financial Results with Record First Quarter Revenue and Adjusted EBITDA(1) from Imaging Center Operations and Revises Upwards 2023 Financial Guidance Ranges for Revenue and Adjusted EBITDA(1)

ANNAPOLIS, Md., May 04, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), today announced that Maryland Governor Wes Moore signed into law legislation to improve lung and breast cancer detection and diagnosis in Maryland. House Bill (HB) 815/Senate Bill (SB) 965 and HB 376/SB 184 require state-regulated insurers to waive patient cost-shares for supplemental diagnostic imaging associated with lung and breast cancers, respectively. The bills were championed by RadNet and received unanimous support from the Maryland House and Senate.

Maryland Governor Moore Signs RadNet-supported Legislation to Make Follow-up Diagnostic Imaging for Breast and Lung Cancers More Affordable

LOS ANGELES, May 01, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc., (NASDAQ: RDNT) today announced that it has received FDA clearance for the third-generation release of its Quantib Prostate™ 3.0 MRI artificial intelligence (AI) software, further enhancing the offering with new and updated tools. Quantib Prostate™ software for MRI reading support was first introduced in the US, followed by a class IIb CE marking in Europe in 2021.

RadNet's Quantib B.V. Subsidiary Receives FDA Clearance for its Quantib Prostate™ 3.0 Software

LOS ANGELES, April 27, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, announced today that it will host a conference call to discuss its first quarter 2023 financial results on Tuesday, May 9, 2023 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

RadNet, Inc. Announces Date of its First Quarter 2023 Financial Results Conference Call

RadNet, Inc. has projected itself to have a strong FY'23 from a period of heavy investment last year. The firm has added numerous de novos and expects to bring more online this year.

RadNet: In For A Big FY 2023, Look For De Novo Contributions

Pennant Group Inc

Viemed Healthcare

Increasing interest rates, higher costs and rising unemployment paint an unfavorable picture with the risk of a recession looming large. Here we discuss three medical stocks that may be good bets even in a recession.

3 Medical Device Stocks With Potential to Fight Recession Risk

Addus HomeCare

Chemed

Despite the macroeconomic challenges, rising dependence on telehealth and the dominance of AI are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. CHE, ADUS, RDNT and PNTG are well poised to gain from the prospects.

4 Promising Stocks From a Challenging Outpatient Home Health Industry

LOS ANGELES, March 21, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the Sidoti & Company Spring 2023 Conference on Wednesday, March 22nd at 01:00 p.m. Eastern Time.

RadNet, Inc. to Present at the Sidoti & Company 2023 Virtual Spring Investor Conference on Wednesday, March 22nd

RadNet (RDNT) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Why Fast-paced Mover RadNet (RDNT) Is a Great Choice for Value Investors

LOS ANGELES, March 13, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer will be presenting at the Barclays Global Healthcare Conference on Thursday, March 16, 2023 at 9:30 a.m. Eastern Time (6:30 a.m. Pacific Time).

RadNet, Inc. to Present at the Barclays Global Healthcare Conference on Thursday, March 16th

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Investors Undervaluing RadNet (RDNT) Right Now?

LOS ANGELES, March 06, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer and Gregory Sorensen, M.D., CEO and co-founder of DeepHealth (RadNet's Artificial Intelligence Division), will be presenting at the Cowen & Company Healthcare Conference on Tuesday, March 7, 2023 at 9:50 a.m. Eastern Time (6:50 a.m. Pacific Time).

RadNet, Inc. to Present at the 43rd Annual Cowen & Company Healthcare Conference on Tuesday, March 7th

RadNet, Inc. (NASDAQ:RDNT ) Q4 2022 Earnings Conference Call February 28, 2023 10:30 AM ET Company Participants Mark Stolper - EVP and CFO Howard Berger - CEO Conference Call Participants Brian Tanquilut - Jefferies John Ransom - Raymond James Mitra Ramgopal - Sidoti & Company Operator Greetings, and welcome to the RadNet Inc. Fourth Quarter 2022 Financial Results Call. At this time, all participants are in a listen-only mode.

RadNet, Inc. (RDNT) Q4 2022 Earnings Call Transcript

RadNet (RDNT) delivered earnings and revenue surprises of -42.11% and 11.24%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

RadNet (RDNT) Misses Q4 Earnings Estimates

LOS ANGELES, Feb. 28, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 357 owned and/or operated outpatient imaging centers, today reported financial results for its fourth quarter and full year ended December 31, 2022.

RadNet Reports Fourth Quarter 2022 Results, Including Record Revenue and Adjusted EBITDA(1), and Releases 2023 Financial Guidance

LOS ANGELES, Feb. 09, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, announced today that it will host a conference call to discuss its fourth quarter 2022 financial results on Tuesday, February 28, 2023 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

UPDATE - RadNet, Inc. Announces Date of its Fourth Quarter 2022 Financial Results Conference Call

LOS ANGELES, Feb. 09, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, announced today that it will host a conference call to discuss its fourth quarter 2022 financial results on Tuesday, February 28, 2022 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

RadNet, Inc. Announces Date of its Fourth Quarter 2022 Financial Results Conference Call

NEW YORK , Feb. 8, 2023 /PRNewswire/ -- RadNet, Inc. (NASDAQ:  RDNT), today announced that it has started implementation of its new Enhanced Breast Cancer Detection (EBCD) service (https://myEBCDmammo.com), which works in concert with a patient's annual breast screening regimen. EBCD includes (i) the application of Saige-Dx™, an FDA-cleared artificial intelligence (AI) technology powered by DeepHealth; (ii) an additional AI-driven review ("Accord") applied to certain suspicious exams and findings; (iii) an in-depth personalized lifetime risk assessment for breast cancer; and (iv) a dedicated 1-800 support line for questions about certain aspects of the patient's reports.

RadNet Launches the Enhanced Breast Cancer Detection Program, Providing Women in New York and New Jersey a New State-of-the-Art Solution Powered by Artificial Intelligence

FORT PIERCE, Fla. , Feb. 6, 2023 /PRNewswire/ -- Radiology Imaging Associates, a division of RadNet, Inc. (NASDAQ: RDNT), today announced that it has started implementation of its new Enhanced Breast Cancer Detection (EBCD) service ( https://myEBCDmammo.com ), which works in concert with a patient's annual breast screening regimen.

Radiology Imaging Associates Launches the Enhanced Breast Cancer Detection Program, Providing Women a New State-of-the-Art Solution Powered by Artificial Intelligence

Hecla Mining

Illumina

MGM Resorts

Omnicell

Investors who can correctly spot overpriced stocks and shun them at the right time can avoid big losses. Dump toxic stocks like MGM, ILMN, OMCL, HL and RDNT to prevent portfolio bleeding.

5 Toxic Stocks That Can Set Off Alarm Bells for Your Portfolio

CAMBRIDGE, Mass. and LOS ANGELES, Dec. 19, 2022 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), today announced that its subsidiary DeepHealth, Inc., a leading developer of artificial intelligence (AI) for mammography interpretation, has received FDA clearance of its mammography density assessment software, Saige-Density™.

RadNet's Artificial Intelligence Subsidiary, DeepHealth, Announces FDA Clearance of its Third AI Mammography Product

In development for 15 de novo facilities across its broad market spectrum, expects another 8 facilities ready by Q2 FY23. Solid growth across core business portfolio, with imaging centres turnover a standout from the last period.

RadNet: Defensive Macro-Positioning Increases Attractiveness, Retain Buy

LOS ANGELES, Dec. 06, 2022 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the Sidoti & Company December 2022 Small-Cap Virtual Conference on Wednesday, December 7, 2022 at 3:15 p.m. Eastern Time.

News for RadNet Stock (RDNT)